Chapter 8

NO CANCER DIRECTED TREATMENT

The group of patients under the category 'No Cancer Directed Treatment' includes patients who have not received or not accepted treatment, those patients who had incomplete treatment and patients in whom the treatment status was not known. The number and proportion of these patients relative to all patients registered in a given centre is shown in Table 8.1 and diagrammatically depicted in Figure 8.1. The relative proportion of patients that fell in this category varied from a low of 15.1% among females in RCC - TVM to a high of 60.0% in males in CI (WIA) - Chennai.

Overall more than one-third of patients do not appear to receive cancer directed treatment, though there is the possibility that some patients may go elsewhere and receive treatment.

Table 8.2 gives the number and relative proportion of patients who did not accept or receive treatment and those who received incomplete treatment. The major group in any centre is those who did not receive (not accepted or not received) treatment, but a good proportion was observed in AMC - Dibrugarh in both sexes who have received incomplete treatment.

Tables 8.3 and 8.4 with their corresponding Figures 8.2 and 8.3 try to examine the No Cancer Directed Treatment group as a whole according to clinical extent of disease. The proportion of patients with localised disease relative to all patients in this category varies from 0.1% among females in CI (WIA) - Chennai to 63.2% in both sexes in BRAIRCH - New Delhi. Looked at in another way (Table 8.4 and Figure 8.3), the proportion of localised cancers that constituted the No Cancer Directed Treatment group varies from 1.3% in CI (WIA) - Chennai to 50.9% in BBCI - Guwahati females. Tables 8.3, 8.4 and Figure 8.3 show the number and relative proportions when the clinical extent of disease was stated as 'Regional', 'Distant', or 'Others'.

Table 8.1: Number of Patients Registered and Number (#) and Relative Proportion (%)
Who had No Cancer Directed Treatment (No CDT)

Registry		Males		Females				
	Total Patients	No (CDT	Total Patients	No CDT			
	Registered	#	%	Registered	#	%		
TMH	14519	6171	42.5	11022	3625	32.9		
KMIO	3897	2202	56.5	4790	2276	47.5		
CI (WIA)	4085	2453	60.0	4469	2078	46.5		
RCC - TVM	11447	2421	21.1	11759	1772	15.1		
AMC	1794	313	17.4	1793	310	17.3		
BBCI	13124	6608	50.4	9438	4750	50.3		
PGIMER	9650	2613	27.1	7532	1895	25.2		
BRAIRCH	4430	1608	36.3	3609	1068	29.6		

Fig. 8.1(a): Proportion of Patients under Category 'No Cancer Directed Treatment'




Fig. 8.1(b): Proportion of Patients under Category 'No Cancer Directed Treatment'




Table 8.2: Number (#) and Relative Proportion (%) by Treatment (Tmt.) Status in Patients with No Cancer Directed Treatment (CDT)


Registry	Not Received		Not Accepted		Incomplete Tmt.		Tmt. Unknown		Total No CDT	
	#	%	#	%	#	%	#	%	#	%
MALES										
TMH	721	11.7	1227	19.9	549	8.9	3674	59.5	6171	100.0
KMIO	1069	48.5	282	12.8	188	8.5	663	30.1	2202	100.0
CI (WIA)	2322	94.7	19	0.8	112	4.6	-	-	2453	100.0
RCC - TVM	1711	70.7	616	25.4	94	3.9	-	-	2421	100.0
AMC	137	43.8	100	31.9	69	22.0	7	2.2	313	100.0
BBCI	5168	78.2	1045	15.8	395	6.0	-	-	6608	100.0
PGIMER	1846	70.6	26	1.0	379	14.5	362	13.9	2613	100.0
BRAIRCH	794	49.4	694	43.2	1	0.1	119	7.4	1608	100.0
FEMALES										
TMH	429	11.8	587	16.2	362	10.0	2247	62.0	3625	100.0
KMIO	809	35.5	298	13.1	230	10.1	939	41.3	2276	100.0
CI (WIA)	1966	94.6	26	1.3	86	4.1	-	-	2078	100.0
RCC - TVM	1194	67.4	503	28.4	75	4.2	-	-	1772	100.0
AMC	145	46.8	120	38.7	37	11.9	8	2.6	310	100.0
BBCI	3881	81.7	589	12.4	280	5.9	-	-	4750	100.0
PGIMER	1382	72.9	35	1.8	183	9.7	295	15.6	1895	100.0
BRAIRCH	594	55.6	395	37.0	1	0.1	78	7.3	1068	100.0

Table 8.3: Number (#) and Relative Proportion (%) of Clinical Extent of Disease in Patients with No Cancer Directed Treatment (CDT)

Registry	Localised		Regional		Distant		Others		Unkı	nown	All	
	#	%	#	%	#	%	#	%	#	%	#	%
MALES												
TMH	404	6.5	1049	17.0	541	8.8	383	6.2	3794	61.5	6171	100.0
KMIO	85	3.9	805	36.6	313	14.2	328	14.9	671	30.5	2202	100.0
CI (WIA)	-	-	1487	60.6	523	21.3	443	18.1	-	-	2453	100.0
RCC - TVM	198	8.2	1185	48.9	511	21.1	527	21.8	-	-	2421	100.0
AMC	3	1.0	197	62.9	61	19.5	49	15.7	3	1.0	313	100.0
BBCI	584	8.8	3236	49.0	1904	28.8	864	13.1	20	0.3	6608	100.0
PGIMER	112	4.3	1185	45.4	454	17.4	501	19.2	361	13.8	2613	100.0
BRAIRCH	1016	63.2	112	7.0	177	11.0	271	16.9	32	2.0	1608	100.0
FEMALES												
TMH	245	6.8	497	13.7	397	11.0	160	4.4	2326	64.2	3625	100.0
KMIO	115	5.1	825	36.2	198	8.7	202	8.9	936	41.1	2276	100.0
CI (WIA)	3	0.1	1483	71.4	358	17.2	234	11.3	-	-	2078	100.0
RCC - TVM	265	15.0	833	47.0	314	17.7	360	20.3	-	-	1772	100.0
AMC	1	0.3	148	47.7	114	36.8	41	13.2	6	1.9	310	100.0
BBCI	493	10.4	1923	40.5	1890	39.8	435	9.2	9	0.2	4750	100.0
PGIMER	218	11.5	685	36.1	408	21.5	289	15.3	295	15.6	1895	100.0
BRAIRCH	675	63.2	66	6.2	162	15.2	143	13.4	22	2.1	1068	100.0

Fig. 8.2: Relative Proportion of Clinical Extent of Disease in Patients with 'No Cancer Directed Treatment'

Males



Females




Table 8.4: Number (#) and Relative Proportion (%) who Received (CDT-Y) and did not Receive (CDT-N) Cancer Directed Treatment in Each Category of Clinical Extent of Disease*

			MALES		FEMALES					
	Total	CDT-Y		CDT-N		Total	otal CDT-Y		CDT-N	
	Cases	#	%	#	%	Cases	#	%	#	%
Localised										
TMH	1023	619	60.5	404	39.5	842	597	70.9	245	29.1
KMIO	212	127	59.9	85	40.1	358	243	67.9	115	32.1
CI (WIA)	81	81	100.0	-	-	226	223	98.7	3	1.3
RCC - TVM	707	509	72.0	198	28.0	1334	1069	80.1	265	19.9
AMC	26	25	96.2	1	3.8	12	11	91.7	1	8.3
BBCI	1202	618	51.4	584	48.6	968	475	49.1	493	50.9
PGIMER	344	232	67.4	112	32.6	1128	910	80.7	218	19.3
BRAIRCH	2062	1046	50.7	1016	49.3	1528	853	55.8	675	44.2
Regional										
TMH	2497	1448	58.0	1049	42.0	1830	1333	72.8	497	27.2
KMIO	1473	668	45.3	805	54.7	2006	1181	58.9	825	41.1
CI (WIA)	2156	669	31.0	1487	69.0	2736	1253	45.8	1483	54.2
RCC - TVM	4790	3605	75.3	1185	24.7	4491	3658	81.5	833	18.5
AMC	871	740	85.0	131	15.0	850	747	87.9	103	12.1
BBCI	6801	3565	52.4	3236	47.6	3897	1974	50.7	1923	49.3
PGIMER	5436	4251	78.2	1185	21.8	3310	2625	79.3	685	20.7
BRAIRCH	238	126	52.9	112	47.1	189	123	65.1	66	34.9
Distant										
TMH	938	397	42.3	541	57.7	797	400	50.2	397	49.8
KMIO	402	89	22.1	313	77.9	327	129	39.4	198	60.6
CI (WIA)	624	101	16.2	523	83.8	497	139	28.0	358	72.0
RCC - TVM	1742	1231	70.7	511	29.3	1057	743	70.3	314	29.7
AMC	105	58	55.2	47	44.8	202	121	59.9	81	40.1
BBCI	2316	412	17.8	1904	82.2	2224	334	15.0	1890	85.0
PGIMER	1263	809	64.1	454	35.9	979	571	58.3	408	41.7
BRAIRCH	346	169	48.8	177	51.2	306	144	47.1	162	52.9
Others										
TMH	1172	789	67.3	383	32.7	478	318	66.5	160	33.5
KMIO	615	287	46.7	328	53.3	359	157	43.7	202	56.3
CI (WIA)	722	279	38.6	443	61.4	385	151	39.2	234	60.8
RCC - TVM	2177	1650	75.8	527	24.2	1439	1079	75.0	360	25.0
AMC	134	100	74.6	34	25.4	68	43	63.2	25	36.8
BBCI	1209	345	28.5	864	71.5	586	151	25.8	435	74.2
PGIMER	1650	1149	69.6	501	30.4	877	588	67.0	289	33.0
BRAIRCH	669	398	59.5	271	40.5	319	176	55.2	143	44.8
Unknown										
TMH	6054	2260	37.3	3794	62.7	4300	1974	45.9	2326	54.1
KMIO	734	63	8.6	671	91.4	1007	71	7.1	936	92.9
CI (WIA) RCC - TVM	-	-	-	-	-	-	-	-	-	-
AMC	- 10	- 8	80.0	- 2	20.0	- 6	3	50.0	3	50.0
BBCI	24	4	16.7	20	83.3	13	4	30.8	9	69.2
PGIMER	362	1	0.3	361	99.7	295	-	-	-	-
BRAIRCH	63	31	49.2	32	50.8	34	12	35.3	22	64.7

^{*} Excludes patients whose clinical extent was unknown.

Fig. 8.3: Proportion of 'No Cancer Directed Treatment' in Each Category of Clinical Extent of Disease

Males



Females

